ClinicalTrials.gg
Drug

Recombinant human thrombopoietin clinical trials

studies test it
48
open now
10
in phase 3
20
first study started
1998

How each study uses recombinant human thrombopoietin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the recombinant human thrombopoietin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

rhTPO
32
Recombinant Human Thrombopoietin
18
Recombinant Human TPO
7
TPIAO
6
Decitabine
3

Studies by the year they started

48 studies that test it; most in 2022 (8)

Studies that test recombinant human thrombopoietin, by start year
YearStudies
19981
20001
20011
20091
20101
20113
20122
20131
20145
20152
20162
20183
20194
20203
20211
20228
20232
20243
20264

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
6
Phase 2
14
Phase 3
20
Phase 4
8
No phase
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 4 · Other 44

Shandong University (9) · Peking Union Medical College Hospital (3) · Huihan Wang (3) · Peking University People's Hospital (3) · Institute of Hematology & Blood Diseases Hospital, China (2) · The First Affiliated Hospital of Zhengzhou University (2) · Nanfang Hospital, Southern Medical University (2) · Shenyang Sunshine Pharmaceutical Co., LTD. (2)

Often tested with

Tested in the same studies.

Hetrombopag (2) · Decitabine (1) · Rituximab (1) · Carboplatin (1) · Etoposide (1) · Ifosfamide (1) · Granulocyte Colony-Stimulating Factor (1) · Lusutrombopag (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Recombinant human thrombopoietin is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 1

Studies that test recombinant human thrombopoietin.

Studies

Open first, then newest update. How each study uses recombinant human thrombopoietin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 48

See all 48 studies that test recombinant human thrombopoietin →

Given beside what is tested · 2 — recombinant human thrombopoietin is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with recombinant human thrombopoietin

Codes

What other systems call recombinant human thrombopoietin · ClinicalTrials.gg INT016402

  • UNII (FDA) E2E529W34DRECOMBINANT HUMAN THROMBOPOIETINOne source FDA
  • NCI Thesaurus C878Recombinant Human ThrombopoietinOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.